Andere Sprachen Iconovo AB

Aktien

A2JF91

SE0010868943

ICO

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:21:02 21.05.2024			% 5 Tage	% 1. Jan.
10.55 ^SEK	+2.93%		+29.29%	-8.66%

15.05.	Iconovo AB (publ) reicht Patentanmeldung für inhalative GLP-1-Produkte ein und beginnt mit der Entwicklung neuer Adipositas-Behandlungen	CI
06.05.	Das schwedische Unternehmen Iconovo erhält ein chinesisches Patent für den ICOres-Inhalator	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioStock: Iconovo initiates development of inhaled obesity treatment	08:15
Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments	15.05.
Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	15.05.
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	06.05.
Iconovo receives patent protection for ICOres® in China	06.05.
Iconovo AB Receives Patent Protection for Icores in China	06.05.
Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon	26.04.
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25.04.
Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®	11.03.
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	11.03.
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea	05.03.
Iconovo Q4 - Aligned with our expectations and a directed issue announcement	19.02.
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.02.
Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report	15.02.
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease	07.02.
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	07.02.
Iconovo launches improved versions of nasal ICOone® inhalers	06.02.
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	06.02.
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Iconovo AB

Aktien

A2JF91

SE0010868943

ICO

Andere Sprachen

Filter